Breanna Qin

Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on its definitive merger agreement to acquire scPharmaceuticals for up to $360 million

Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion.

Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.

Cooley advised Rubrik (NYSE: RBRK), a leading cybersecurity company, on its agreement to acquire Predibase to accelerate agentic artificial intelligence adoption from pilot to production at scale. 

Cooley advised SoftEye, a San Diego-based company developing specialized chips, cameras, software and algorithms for use in smart glasses, on its sale to TDK Corporation, a Tokyo-based global leader in advanced electronic solutions designed for a smarter, more connected world.